COVID-19 therapy trial underway, RSV trial to follow
Nanoviricides (NV) has announced its first clinical study, a key milestone in the development of its novel and innovative anti-virus therapy, NV-CoV-2. The technology uses a sophisticated large polymer (NV-387) to trap and disrupt viruses in the blood. The therapy aims to reduce the viral load to pNanoViricides is engaged in the development of drugs to combat viral infections. The company is a development stage company with several drugs in various stages of pre-clinical development, including Investigational New Drug-enabling non-clinical studies. The company's primary focus is bringing its topical treatment for shingles into human clinical trials. Several additional indications in the HerpeCide? program, including skin creams for the treatment of genital ulcers, and for the treatment of cold sores should follow the shingles candidate into clinical development. In addition, the company has drug candidates in development against severe influenzas and other viruses at different preclinical stages.
Capital Network is the foremost authority on utilising digitisation to allow companies to achieve their corporate goals, whether those goals pertain to raising capital, increasing investor awareness, boosting liquidity or allowing the business to flourish. We are proud to deliver bespoke, industry-leading services to a broad range of capital market clients. To deliver on our range of digitised services clients are assigned tier-1 analysts who have extensive sector knowledge, numerous accreditations and a track record of delivering success.
The investor community is evolving and we allow investment banks, fund managers, hedge funds, wealth managers, trusts, family offices and private investors the capacity to access new investment ideas as well delivering further insight into their current portfolio. In addition to driving value for our diverse client base, we empower investors with our digital solutions.
Our approach to serving clients takes a traditional method of doing first-class business in a first-class way, in conjunction with implementing the most technologically advanced services for them. We strive to build trusted, long-term relationships built on diligence and foresight, and identifying ways to help clients achieve their most important business objectives.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.